Modern features of acute bronchitis therapy. The effect and advantages of the dispersible form of antibacterial drugs

Acute bronchitis is one of the most common reasons for patients seeking medical care on an outpatient basis, the incidence of it reaches 30-40% and depends both on seasonality (from late December to early March) and on the epidemiological characteristics of the population under study (children's organized groups, military personnel in long-term care facilities) and on the epidemic rise in the incidence of influenza. The actual incidence of acute bronchitis may be higher, which is associated with self-medication and the lack of seeking medical help for mild forms of the disease. This article discusses modern approaches to understanding the problem of acute bronchitis. The decisive role of respiratory viruses in the etiology of this disease, predisposing factors to its development and the main pathogenetic links and mechanisms are emphasized. At the same time, Mycoplasma pneumoniae and Chlamydophila pneumoniae, as well as Bordetella pertussis, are shown to be crucial in the formation of prolonged forms of acute bronchitis due to the long persistence of these microorganisms. Emphasis is placed on pathogenetic and symptomatic therapy, which is sufficient in the treatment of 90% of cases of this disease. Errors and unreasonable prescriptions of antibacterial drugs for acute bronchitis are considered. At the same time, the necessity of etiotropic (antibacterial) therapy in the case of a disease caused by intracellular pathogens, taking into account modern clinical recommendations, is emphasized. Indications for the appointment of macrolides, features and advantages of the clinical use of azithromycin, as well as its non-antibacterial properties are considered. The advantages of the dosage form of the dispersed tablets in comparison with traditional dosage forms for oral administration are evaluated. The pharmacokinetic advantages of dispersible tablets in the form of their improved bioavailability, their favorable safety profile and ease of use in various categories of patients, as well as potentially higher clinical efficacy are analyzed.

1. Bentsa T. M. Pharmacotherapy of acute bronchitis // Ліки України. 2018; 220 (4): 19-22.

2. Zaytsev A. A. Acute bronchitis: clinical guidelines // Meditsinskiy sovet. 2020; (17): 27-32.

3. Zaryankina A. I., Kozlovskiy A. A. Bronchitis in children: study guide. manual for students of 4-6 courses of all faculties of institutions of higher medical education, interns, pediatricians, general practitioners, students of advanced training and retraining courses.

4. A. A. Kozlovskiy. Gomel: GomGMU, 2018. P. 20.

5. Bronchitis. Clinical recommendations of the Ministry of Health of the Russian Federation. M., 2021. P. 56.

6. Kinkade S., Long N.A. Acute Bronchitis // Am Fam Physician. 2016; 94 (7): 560-565.

7. Okovityy S. V., Zaytsev A. A., Anisimova N. A. Pharmacodynamic approaches to the use of mucoactive drugs // The Lechaschi Vrach Journal. 2020; 10: 6-10.

8. Okovityy S. V., Mar'yushkina V. S., Sukhanov D. S., Selizarova N. O. Pharmacological approaches to the rational choice of combined mucoactive drugs // The Lechaschi Vrach Journal. 2021; 12: 41-45.

9. Smith S. M., Fahey T., Smucny J., Becker L. A. Antibiotics for acute bronchitis // Cochrane Database Syst Rev. 2017; 6 (6): CD000245. DOI: 10.1002/14651858.

10. Killeen B. M., Wolfson A. B. Antibiotics for Acute Bronchitis // Am Fam Physician. 2020; 102 (9): Online.

11. Butler C. C., Kelly M. J., Hood K., Schaberg T., Melbye H., Serra-Prat M., Blasi F., Little P., Verheij T., Mölstad S., Godycki-Cwirko M., Edwards P., Almirall J., Torres A., Rautakorpi U. M., Nuttall J., Goossens H., Coenen S. Antibiotic prescribing for discoloured sputum in acute cough/lower respiratory tract infection // Eur Respir J. 2011; 38 (1): 119-125. DOI: 10.1183/09031936.00133910.

12. Oeffinger K. C., Snell L. M., Foster B. M., Panico K. G., Archer R. K. Treatment of acute bronchitis in adults // J Fam Pract. 1998; 46 (6): 469-475.

13. Morley V. J., Firgens E. P. C., Vanderbilt R. R., Zhou Y., Zook M., Read A. F., MacGeorge E. L. Factors associated with antibiotic prescribing for acute bronchitis at a university health center // BMC Infect Dis. 2020; 20 (1): 177. DOI: 10.1186/s12879-020-4825-2.

14. Zaplatnikov A. L., Maykova I. D., Lepiseva I. V. Respiratory mycoplasmosis in the practice of a pediatrician // Meditsinskiy sovet. 2016; 1: 157-161.

15. Belovol A. L. Clinical significance of the pharmacological effects of azithromycin // Liki Ukrainy. 2008; 5: 34-39.

16. Tamaoki J. The effects of macrolides on inflammatory cells // Chest. 2004; 125 (2 Suppl): 41S-51S.

17. Uriate S. M., Molestina R. E., Miller R. D., Bernabo J., Farinati A., Eiguchu K., Ramirez J. A., Summersgill J. T. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alfa // J Infect Dis. 2002; 185: 1631-1636.

18. Asgrimsson V. , Gudjonsson T., Gudmundsson G. H., Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia // Antimicrob. Agents Chem. 2006; 50 (5) :1805-1812.

19. Strategy and tactics of rational use of antimicrobial agents in outpatient practice: Eurasian clinical guidelines / Pod red. S. V. Yakovleva, S. V. Sidorenko, V. V. Rafal'skogo, T. V. Spichak. M.: Izdatel'stvo «Pre100Print», 2016. P. 144.

20. Zyryanov S. K., Baybulatova Ye. A. The use of new dosage forms of antibiotics as a way to improve the effectiveness and safety of antibacterial therapy // Antibiotiki i khimioterapiya. 2019; 64 (3-4): 81-91.

21. Ushkalova Ye. A. The value of dosage forms for rational antibiotic therapy. Solutab dosage form // Vrach. 2007; 3: 63-66.

22. Kucers’ the use of antibiotics : a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs / [Edited by] M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, William Hope, James S. Mccarthy, John Mills, Johan W. Mouton and David L. Paterson. Seventh edition. 2018. Taylor & Francis Group. 4891 р.

23. Tatochenko V. K. Antibiotics in the dosage form Solutab // Farmateka. 2010; 14: 46-50.